Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats

Sorafenib (SOR), an inhibitor of multiple kinases, is a classic targeted drug for advanced hepatocellular carcinoma (HCC) which often coexists with type 2 diabetes mellitus (T2DM). Dapagliflozin (DAPA), a sodium–glucose cotransporter-2 inhibitor (SGLT2i), is widely used in patients with T2DM. Notabl...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xueru, Li, Ying, Ma, Yinling, Fu, Yuhao, Xun, Xuejiao, Cui, Yanjun, Dong, Zhanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571628/
https://www.ncbi.nlm.nih.gov/pubmed/36234746
http://dx.doi.org/10.3390/molecules27196190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571628/
https://www.ncbi.nlm.nih.gov/pubmed/36234746
http://dx.doi.org/10.3390/molecules27196190

Ejemplares similares